The Site of the Breakpoint Within the bcr Is a Prognostic Factor in Philadelphia-Positive CML Patients

• Published in: Blood Vol. 72; no. 4; pp. 1237 - 1241
• Main Authors: Mills, Ken I., MacKenzie, Elaine D., Birnie, George D.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01.10.1988; The Americain Society of Hematology
• Subjects: Biological and medical sciences; Blotting, Southern; Hematologic and hematopoietic diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myeloid, Chronic-Phase - genetics; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Nucleic Acid Hybridization; Philadelphia Chromosome; Prognosis; Time Factors; Translocation, Genetic; Chromosomal aberration; Human; Abnormal «G22» chromosome; Molecular hybridization; Ph1-Chromosome; Prognosis; Chronic myelocytic leukemia; Abnormal chromosome; Hemopathy; Molecular biology; Localization; Tumor cell
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V72.4.1237.1237

The Philadelphia (Ph1) chromosome, characteristic of chronic myelogenous leukemia (CML), arises from a reciprocal translocation between chromosomes 9 and 22. The site of the breakpoint on chromosome 22 is within a small region called the breakpoint cluster region (bcr). We have mapped the breakpoint within the bcr in peripheral blood leukocyte DNA from 22 Prepositive CML patients. No correlation between the site of the breakpoint and the clinical phase of the disease was found. However, a striking correlation between the site of the breakpoint and the length of time between presentation and onset of acute phase was observed: on average, patients with a5′ breakpoint had a fourfold longer chronic phase (median, 203 weeks) than those with a3′ breakpoint (median, 52 weeks).